+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • May 2023
  • Region: Global
  • Grand View Research
  • ID: 5830909
Description Jump to:
The global intravenous immunoglobulin market size is expected to reach USD 21.05 billion by 2030, registering a CAGR of 7.3% over the forecast period. The increasing prevalence of immunodeficiency diseases, coupled with the adoption of intravenous immunoglobulin (IVIG) therapies, is expected to fuel market growth over the forecast period. In addition, increasing off-label use of immunoglobulin and investments in the healthcare sector are factors propelling the market growth. Moreover, increasing incidences of bleeding disorders and the growing geriatric population are the factors contributing to the industry growth.

The rising incorporation of subcutaneous immunoglobulin in the treatment of primary immunodeficiency diseases as well as in replacement therapy is anticipated to provide a growth platform to the market in the next seven years. Moreover, the key market players are focusing on breakthrough product introductions to expand their global distribution network. For instance, Octapharma U. S. got FDA clearance in July 2021 for Octagam 10%, its first intravenous immunoglobulin recommended for the treatment of the immune-mediated inflammatory illness known as dermatomyositis in adults.

The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide market for intravenous immunoglobulin. In India, for instance, Bharat Biotech is conducting a study to create monoclonal antibodies as a potential COVID-19 treatment. The Council of Scientific and Industrial Research (CSIR) has approved the project as part of its New Millennium Indian Technology Leadership strategy. Moreover, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. For instance, in April 2021, Grifols, a key provider of plasma-derived medicines, contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients. This is expected to provide a boost to the market growth in the forecast period.

Key players are adopting strategic alliances to sustain the competition. These initiatives include mergers & acquisitions, collaborations, and new product developments. For instance, in March 2022, Grifols' XEMBIFY has been approved in Europe, increasing access to novel medicines. Grifols' clearance in Europe allows it to extend its breakthrough European IG product range and offer patients and healthcare professionals another crucial therapy solution for primary and secondary immunodeficiencies. In February 2021, Pfizer gained US FDA clearance for the supplemental Biologics License Application (sBLA) with PANZYGA, an intravenous immunoglobulin to cure adult patients with severe inflammatory demyelinating polyneuropathy (CIDP).

Intravenous Immunoglobulin Market Report Highlights

  • The hypogammaglobulinemia application segment held the third-largest revenue share in 2022. This can be attributed to the increasing demand for immunoglobulin replacement therapies to treat hypogammaglobulinemia diseases, which is driven by rising awareness levels amongst patients and increasing incidences of the disease
  • The hospital pharmacy distribution channel segment dominated the market with a revenue share of over 57.83% in 2022 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies
  • The specialty pharmacy distribution channel segment is anticipated to expand at a lucrative CAGR during the forecast period as specialty pharmacies enable easy treatment at home
  • North America held the largest share of 46.51% in terms of revenue in 2022 due to the presence of a well-regulated healthcare system, the larger pool of target population, and high patient awareness pertinent to the plasma protein products
  • Asia Pacific is expected to register a significant CAGR of 8.4% over the forecast period owing to the increasing number of patients with bleeding disorders and the growing number of CIDP patients
  • Countries such as India, China, and South Africa are expected to witness significant growth over the forecast period owing to improving healthcare facilities, rising healthcare expenditure, and growing public awareness regarding immune deficiency disorders
  • The Kawasaki disease application segment is expected to expand at a lucrative CAGR of 9.6% from 2023 to 2030 owing to the massive adoption of IVIG treatment in the aforementioned disease management


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Definitions
1.1.1.1 Test Segment
1.1.1.2 Service Provider Segment
1.1.1.3 Application Segment
1.2 Regional Scope
1.3 Estimates and Forecast Timeline
1.4 Objectives
1.4.1 Objective - 1
1.4.2 Objective - 2
1.4.3 Objective - 3
1.5 Research Methodology
1.6 Information Procurement
1.6.1 Purchased Database
1.6.2 Internal Database
1.6.3 Secondary Sources
1.6.4 Primary Research
1.7 Information or Data Analysis
1.7.1 Data Analysis Models
1.8 Market Formulation & Validation
1.9 Model Details
1.9.1 Commodity Flow Analysis
1.10 List of Secondary Sources
1.11 List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Application and Distribution Channel Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Rising prevalence of immunodeficiency diseases
3.4.2. Increasing adoption of immunoglobulin replacement therapy
3.4.3. Rising geriatric population
3.5. Market Restraint Analysis
3.5.1. Cost intensive nature of immunoglobulin replacement therapy
3.5.2. Stringent regulations pertaining to production and approval
3.6. Industry Challenges
3.6.1. Quality assurance and standardization-related challenges
3.6.2. Limited scope for multiple evaluations
3.7. Business Environment Analysis
3.7.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.7.2. Porter’s Five Forces Analysis
3.8. COVID-19 Impact Analysis
Chapter 4. Intravenous Immunoglobulin Market: Segment Analysis by Application, 2018 - 2030 (USD Million)
4.1. Intravenous Immunoglobulin Market: Application Movement Analysis
4.2. Intravenous Immunoglobulin Market: Application Estimates and Forecasts, By Application (USD Million)
4.3. Hypogammaglobulinemia
4.3.1. Hypogammaglobulinemia Market, 2018 - 2030 (USD Million)
4.4. CIPD
4.4.1. CIPD Market, 2018 - 2030 (USD Million)
4.5. Immunodeficiency Diseases
4.5.1. Immunodeficiency Diseases Market, 2018 - 2030 (USD Million)
4.6. Congenital AIDS
4.6.1. Congenital AIDS Market, 2018 - 2030 (USD Million
4.7. Chronic Lymphocytic Leukemia
4.7.1. Chronic Lymphocytic Leukemia Market, 2018 - 2030 (USD Million)
4.8. Leukemia Myasthenia gravis
4.8.1. Myasthenia gravis Market, 2018 - 2030 (USD Million)
4.9. Multifocal motor neuropathy
4.9.1. Multifocal motor neuropathy Market, 2018 - 2030 (USD Million)
4.10. ITP
4.10.1. Leukemia ITP Market, 2018 - 2030 (USD Million)
4.11. Kawasaki disease
4.11.1. Kawasaki Disease Market, 2018 - 2030 (USD Million)
4.12. Guillain-Barre syndrome
4.12.1. Guillain-Barre syndrome Market, 2018 - 2030 (USD Million)
4.13. Others
4.13.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Intravenous Immunoglobulin Market: Segment Analysis by Distribution Channel, 2018 - 2030 (USD Million)
5.1. Intravenous Immunoglobulin Market: Distribution Channel Movement Analysis
5.2. Intravenous Immunoglobulin Market: Distribution Channel Estimates and Forecasts, (USD Million)
5.3. Hospital Pharmacy
5.3.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
5.4. Specialty Pharmacy
5.4.1. Specialty Pharmacy Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Intravenous Immunoglobulin Market: Regional Analysis, 2018 - 2030 (USD Million)
6.1. Intravenous Immunoglobulin Market: Regional Outlook
6.2. North America
6.2.1. SWOT Analysis
6.2.2. North America Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. Reimbursement Scenario
6.2.3.6. U.S. Intravenous immunoglobulin Market, 2018 - 2030 (USD MILLION)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Reimbursement Scenario
6.2.4.6. Canada Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3. Europe
6.3.1. SWOT Analysis
6.3.2. Europe Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. Reimbursement Scenario
6.3.3.6. Germany Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.4. UK
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Reimbursement Scenario
6.3.4.6. UK Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. Reimbursement Scenario
6.3.5.6. France Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Reimbursement Scenario
6.3.6.6. Italy Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Reimbursement Scenario
6.3.7.6. Spain Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Reimbursement Scenario
6.3.8.6. Denmark Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Reimbursement Scenario
6.3.9.6. Sweden Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Reimbursement Scenario
6.3.10.6. Norway Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. SWOT Analysis
6.4.2. Asia Pacific Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Reimbursement Scenario
6.4.3.6. Japan Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. Reimbursement Scenario
6.4.4.6. China Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. Reimbursement Scenario
6.4.5.6. India Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4.6. South Korea
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Reimbursement Scenario
6.4.6.6. South Korea Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4.7. Australia
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Reimbursement Scenario
6.4.7.6. Australia Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.4.8. Thailand
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. Reimbursement Scenario
6.4.8.6. Thailand Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Reimbursement Scenario
6.5.3.6. Brazil Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Reimbursement Scenario
6.5.4.6. Mexico Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Reimbursement Scenario
6.5.5.6. Argentina Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. Reimbursement Scenario
6.6.3.6. South Africa Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Reimbursement Scenario
6.6.4.6. Saudi Arabia Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. Reimbursement Scenario
6.6.5.6. UAE Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Reimbursement Scenario
6.6.6.6. Kuwait Intravenous immunoglobulin Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1 Company Categorization
7.2 Strategy Mapping
7.2.1 NEW PRODUCT LAUNCH
7.2.2 PARTNERSHIPS
7.2.3 ACQUISITION
7.2.4 COLLABORATION
7.2.5 FUNDING
7.3 Key Company Market Share Analysis, 2022
7.4 Company Profiles
7.4.1 Biotest AG
7.4.1.1 Company overview
7.4.1.2 Financial performance
7.4.1.3 Product benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 Baxter International Inc.
7.4.2.1 Company overview
7.4.2.2 Financial performance
7.4.2.3 Product benchmarking
7.4.2.4 Strategic Initiatives
7.4.3 Octapharma AG
7.4.3.1 Company overview
7.4.3.2 Financial performance
7.4.3.3 Product benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 LFB Biotechnologies
7.4.4.1 Company overview
7.4.4.2 Product benchmarking
7.4.4.3 Strategic Initiatives
7.4.5 Grifols SA
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 CSL Behring
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 China Biologics Products Inc.
7.4.7.1 Company overview
7.4.7.2 Financial performance
7.4.7.3 Product benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 Kedrion Biopharma
7.4.8.1 Company overview
7.4.8.2 Financial performance
7.4.8.3 Product benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 BDI Pharma Inc
7.4.9.1 Company overview
7.4.9.2 Financial performance
7.4.9.3 Product benchmarking
7.4.9.4 Strategic Initiatives
Chapter 8. KOL Recommendations/ Conclusion
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global Intravenous Immunoglobulin Market, by Region, 2018 - 2030 (USD Million)
Table 4. Global Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 5. Global Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 6. North America Intravenous Immunoglobulin Market, by Country, 2018 - 2030 (USD Million)
Table 7. North America Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 8. North America Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 9. U.S. Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 10. U.S. Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 11. Canada Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 12. Canada Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 13. Europe Intravenous Immunoglobulin Market, by Country, 2018 - 2030 (USD Million)
Table 14. Europe Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 15. Europe Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 16. Germany Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 17. Germany Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 18. UK Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 19. UK Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 20. France Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 21. France Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 22. Italy Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 23. Italy Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 24. Spain Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 25. Spain Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 26. Denmark Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 27. Denmark Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 28. Sweden Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 29. Sweden Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 30. Norway Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 31. Norway Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 32. Asia Pacific Intravenous Immunoglobulin Market, by Country, 2018 - 2030 (USD Million)
Table 33. Asia Pacific Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 34. Asia Pacific Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 35. China Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 36. China Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 37. Japan Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 38. Japan Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 39. India Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 40. India Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 41. South Korea Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 42. South Korea Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 43. Australia Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 44. Australia Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 45. Thailand Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 46. Thailand Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 47. Latin America Intravenous Immunoglobulin Market, by Country, 2018 - 2030 (USD Million)
Table 48. Latin America Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 49. Latin America Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 50. Brazil Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 51. Brazil Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 52. Mexico Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 53. Mexico Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 54. Argentina Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 55. Argentina Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 56. Middle East & Africa Intravenous Immunoglobulin Market, by Country, 2018 - 2030 (USD Million)
Table 57. Middle East & Africa Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 58. Middle East & Africa Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 59. South Africa Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 60. South Africa Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 61. Saudi Arabia Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 62. Saudi Arabia Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 63. UAE Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 64. UAE Intravenous Immunoglobulin Market, By Distribution Channel , 2018 - 2030 (USD Million)
Table 65. Kuwait Intravenous Immunoglobulin Market, by Application, 2018 - 2030 (USD Million)
Table 65. Kuwait Intravenous Immunoglobulin Market, By Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig 1. Market research process
Fig 2. Information Procurement
Fig 3. Primary Research Pattern
Fig 4. Market Research Approaches
Fig 5. Value Chain-Based Sizing & Forecasting
Fig 6. Market Formulation & Validation
Fig 7. Intravenous Immunoglobulin, Market Segmentation
Fig 8. Market Snapshot, 2022
Fig 9. Market Trends & Outlook
Fig 10. Market Driver Relevance Analysis (Current & Future Impact)
Fig 11. Market Restraint Relevance Analysis (Current & Future Impact)
Fig 12. Market Challenge Relevance Analysis (Current & Future Impact)
Fig 13. SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig 14. Porter’s Five Forces Analysis
Fig 15. Global Intravenous Immunoglobulin Market: By Application Movement Analysis
Fig 16. Global Intravenous Immunoglobulin Market, for Immunodeficiency Diseases, 2018 - 2030 (USD Million)
Fig 17. Global Intravenous Immunoglobulin Market, for CIDP, 2018 - 2030 (USD Million)
Fig 18. Global Intravenous Immunoglobulin Market, for Hypogammaglobulinemia, 2018 - 2030 (USD Million)
Fig 19. Global Intravenous Immunoglobulin Market, for Congenital AIDS, 2018 - 2030 (USD Million)
Fig 20. Global Intravenous Immunoglobulin Market, for Chronic Lymphocytic Leukemia, 2018 - 2030 (USD Million)
Fig 21. Global Intravenous Immunoglobulin Market, for Myasthenia Gravis, 2018 - 2030 (USD Million)
Fig 22. Global Intravenous Immunoglobulin Market, for Multifocal motor neuropathy, 2018 - 2030 (USD Million)
Fig 23. Global Intravenous Immunoglobulin Market, for ITP, 2018 - 2030 (USD Million)
Fig 24. Global Intravenous Immunoglobulin Market, for Kawasaki disease, 2018 - 2030 (USD Million)
Fig 25. Global Intravenous Immunoglobulin Market, for Guillain-Barre syndrome2018 - 2030 (USD Million)
Fig 26. Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
Fig 27. Global Intravenous Immunoglobulin Market: Distribution Channel Movement Analysis
Fig 28. Global Intravenous Immunoglobulin Market, for Hospital Pharmacy, 2018 - 2030 (USD Million)
Fig 29. Global Intravenous Immunoglobulin Market, for Specialty Pharmacy, 2018 - 2030 (USD Million)
Fig 30. Global Intravenous Immunoglobulin Market, for Others, 2018 - 2030 (USD Million)
Fig 31. Regional Marketplace: Key Takeaways Intravenous Immunoglobulin Market, Region 2018 - 2030 (USD Million)
Fig 32. Regional Outlook, 2022 & 2030 Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 33. Global Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 34. North America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 35. U.S. Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 36. Canada Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 37. Europe Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 38. Germany Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 39. UK Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 40. France Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 41. Italy Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 42. Spain Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 43. Denmark Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 44. Sweden Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 45. Norway Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 46. Asia Pacific Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 47. Japan Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 48. China Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 49. India Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 50. Australia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 51. South Korea Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 52. Thailand Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 53. Latin America Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 54. Brazil Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 55. Mexico Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 56. Argentina Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 57. Middle East and Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 58. South Africa Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 59. Saudi Arabia Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 60. UAE Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)
Fig 61. Kuwait Intravenous Immunoglobulin Market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Biotest AG
  • Baxter International Inc.
  • Octapharma AG
  • LFB Biotechnologies
  • Grifols SA
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedMay 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 11.98 Billion
Forecasted Market Value ( USD ) by 2030 $ 21.05 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Global Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Forecast 2024-2030 - Product Image

Global Intravenous Immunoglobulin Market by Indication (Primary Immunodeficiency, Secondary Immunodeficiency), Form (Liquid IVIG, Lyophilized IVIG), End-User - Forecast 2024-2030

  • Report
  • 190 Pages
  • Global
From
Intravenous Immunoglobulin Global Market Report 2024 - Product Image

Intravenous Immunoglobulin Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Intravenous Immunoglobulin Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Intravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 297 Pages
  • Global
Global Intravenous Immunoglobulin Market Report and Forecast 2023-2031 - Product Image

Global Intravenous Immunoglobulin Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.